الفهرس 
Introduction and aim of workOnly 14 pages are availabe for public view
 |  | from | 125 |  |  |
| | | from | 125 | | |
Abstract
Acute Myeloid Leukemia (AML) is a clonal hematopoietic disorder that may be derived from either a hematopoietic stem cell or a lineage-specific progenitor cell.
This study aimed to determine the prognostic relevance of CD25 (IL2 receptor-α) and CD123 (IL-3R α) expression in patients with de novo Acute Myeloid Leukemia (AML).
The present study was carried out on 44 patients of newly diagnosed denovo acute myeloid leukemia (AML). They had been followed up until remission or death for periods up to 18 months from March 2013 to October 2014.
Statistical analysis of the results shows the following:
• Median age was 35years; they were 27 males (61.4%) and 17 females (38.6%).
• The commonest presentation was hepato-spleenomegally, followed by bleeding tendency, then lymph node enlargement, then pallor and lastly fever.
• All cases were positive for cMPO, 97.7% of them were CD13, CD33, CD117 positive, 88.6% of them were HLA-DR positive and 84.1% were CD34 positive. while 29.5% of them were CD11c and CD64 positive.
• 54.5% of studied group were with poor cytogenetic risk and 45.5% were good risk group.